Carregant...
Design of small molecules that compete with nucleotide binding to an engineered oncogenic KRAS allele
RAS mutations are found in 30% of all human cancers, with KRAS the most frequently mutated among the three RAS isoforms (KRAS, NRAS, HRAS). However, directly targeting oncogenic KRAS with small molecules in the nucleotide-binding site has been difficult due to the high affinity of KRAS for GDP and G...
Guardat en:
| Publicat a: | Biochemistry |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5960803/ https://ncbi.nlm.nih.gov/pubmed/29313669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.biochem.7b01113 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|